Standard BioTools sells Mass Cytometry business to Multiplex Bio, receives $30M from Illumina buyout

STANDARD BIOTOOLS INC.

Sells Mass Cytometry business (CyTOF/Hyperion) to Multiplex Bio for up to $10M; provides up to $10M working capital loan.
Received ~$30M cash from Illumina to waive 2026 earnout and terminate royalty/license agreements from SomaLogic acquisition.
Early termination of HSR waiting period for Treeline merger; merger expected to close by end of 2026.
Multiplex Bio led by industry veterans; business to continue under Standard BioTools brand.
Transactions subject to stockholder approval and customary conditions; expected to close concurrently with Treeline merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.